Posted by Michael Wonder on 19 Feb 2023
Teva announces FDA approval of Austedo XR (deutetrabenazine) extended release tablets, a new once daily formulation of Austedo (deutetrabenazine) tablets
17 February 2023 - New once daily Austedo XR regimen now approved in 6 mg, 12 mg and 24 mg tablet strengths.
Teva Pharmaceuticals today announced that the US FDA has approved Austedo XR (deutetrabenazine) extended release tablets, a new once daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’s disease.
